Olympus (Tokyo, Japan) has entered into an agreement to acquire Quest Photonic Devices (Quest; Middenmeer, Netherlands) for up to ~$6.7 million, including milestone payments to strengthen its surgical endoscopy capabilities. Quest offers advanced fluorescence imaging systems for the medical field, enabling more surgical endoscopy capabilities when compared to conventional imaging technologies.
Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus’ existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. The system uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures with lower complication risks.
The Quest technology acquired is intended to expand opportunities for Olympus in surgical endoscopy, as Quest’s multispectral imaging and imaging systems for medical applications range from fluorescence imaging to photodynamic therapy. The acquisition will strengthen Olympus’ position in medical imaging solutions, with the ability to deliver capabilities that include 3D and 4K imaging to surgeons. Quest's lead product line is the Quest Spectrum fluorescence imaging system, which enables fluorescence-guided surgery for open and minimally invasive procedures.
Source: Olympus press release via ACN Newswire – January 28, 2021